Biotechnology Assets Past Earnings Performance
Past criteria checks 4/6
Biotechnology Assets has been growing earnings at an average annual rate of 56.8%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 49.5% per year. Biotechnology Assets's return on equity is 24.1%, and it has net margins of 40.3%.
Key information
56.8%
Earnings growth rate
60.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -49.5% |
| Return on equity | 24.1% |
| Net Margin | 40.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Biotechnology Assets makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4 | 2 | 3 | 0 |
| 31 Dec 22 | 3 | -2 | 3 | 0 |
| 30 Sep 22 | 3 | -2 | 3 | 0 |
| 30 Jun 22 | 3 | -2 | 3 | 0 |
| 31 Mar 22 | 3 | -3 | 3 | 0 |
| 31 Dec 21 | 3 | -3 | 3 | 0 |
| 30 Sep 21 | 3 | -3 | 3 | 0 |
| 30 Jun 21 | 3 | -2 | 3 | 0 |
| 31 Mar 21 | 3 | -2 | 3 | 0 |
| 31 Dec 20 | 3 | -2 | 2 | 0 |
| 30 Jun 20 | -17 | -2 | -9 | 0 |
| 31 Mar 20 | -7 | -2 | -2 | 0 |
| 31 Dec 19 | 3 | -3 | 4 | 0 |
| 30 Sep 19 | 41 | -11 | 30 | 0 |
| 30 Jun 19 | 38 | -11 | 29 | 0 |
| 31 Mar 19 | 31 | -14 | 28 | 0 |
| 31 Dec 18 | 25 | -17 | 27 | 0 |
| 30 Sep 18 | 21 | -15 | 24 | 0 |
| 30 Jun 18 | 16 | -14 | 20 | 0 |
| 31 Mar 18 | 15 | -13 | 18 | 0 |
| 31 Dec 17 | 13 | -12 | 17 | 0 |
| 31 Dec 16 | 6 | -3 | 8 | 0 |
| 31 Dec 15 | 5 | -8 | 6 | 0 |
Quality Earnings: 041 has high quality earnings.
Growing Profit Margin: 041 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 041 has become profitable over the past 5 years, growing earnings by 56.8% per year.
Accelerating Growth: 041 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 041 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 041's Return on Equity (24.1%) is considered high.